Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Regulatory approval for ofatumumab in the US is expected in September 2020 and in Europe by Q2 2021.